Compare NWN & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NWN | VRDN |
|---|---|---|
| Founded | 1859 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Medical Specialities |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.1B |
| IPO Year | 2018 | 2014 |
| Metric | NWN | VRDN |
|---|---|---|
| Price | $50.36 | $23.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 14 |
| Target Price | ★ $54.33 | $35.46 |
| AVG Volume (30 Days) | 180.1K | ★ 1.9M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.71% | N/A |
| EPS Growth | ★ 36.45 | N/A |
| EPS | ★ 2.33 | N/A |
| Revenue | ★ $1,289,363,000.00 | $5,706,000.00 |
| Revenue This Year | $11.37 | $13.73 |
| Revenue Next Year | $4.46 | $279.00 |
| P/E Ratio | $21.83 | ★ N/A |
| Revenue Growth | ★ 11.83 | N/A |
| 52 Week Low | $40.09 | $13.18 |
| 52 Week High | $55.99 | $34.29 |
| Indicator | NWN | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 51.24 | 68.75 |
| Support Level | $48.33 | $17.97 |
| Resistance Level | $51.20 | $33.71 |
| Average True Range (ATR) | 0.91 | 1.03 |
| MACD | 0.05 | 0.13 |
| Stochastic Oscillator | 54.65 | 88.31 |
Northwest Natural Holding Co is a public natural gas service supplier operating in the U.S. Pacific Northwest. Its subsidiary, NW Natural, operates through the natural gas distribution segment, which purchases and distributes natural gas through which operates in Oregon and southwest Washington. The company operates in three reportable business segments, which are NWN Gas Utility, SiEnergy, and NWN Water. The company generates maximum revenue from NWN Gas Utility segment. It also generates revenue from residential, commercial, and industrial customers, the majority of which are in Oregon. Residential and commercial customers account for the vast majority of profitability.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.